Premium
The importance of co‐delivery of nanoparticle‐siRNA and anticancer agents in cancer therapy
Author(s) -
Khelghati Nafiseh,
Soleimanpour Mokhtarvand Jafar,
Mir Mostafa,
Alemi Forough,
Asemi Zatollah,
Sadeghpour Alireza,
Maleki Masomeh,
Samadi Kafil Hossein,
Jadidiniaragh Farhad,
Majidinia Maryam,
Yousefi Bahman
Publication year - 2021
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13824
Subject(s) - cancer , rna interference , cancer therapy , small interfering rna , drug delivery , apoptosis , cancer cell , combination therapy , cancer research , cell cycle , medicine , bioinformatics , pharmacology , biology , nanotechnology , rna , gene , materials science , biochemistry
Abstract According to global statistics, cancer is the second leading cause of death worldwide. Because of the heterogeneity of cancer, single‐drug therapy has many limitations due to low efficacy. Therefore, combination therapy with two or more therapeutic agents is being arisen. One of the most important approaches in cancer therapy is the shot down of key genes involved in apoptotic processes and cell cycle. In this regard, siRNA is a good candidate, a highly attractive method to suppressing tumor growth and invasion. Combination therapy with siRNAs and chemotherapeutic agents can overcome the multidrug resistance and increase apoptosis. The efficient delivery of siRNA to the target cell/tissue/organ has been a challenge. To overcome these challenges, the presence of suitable delivery systems by using nanoparticles is interesting. In this review, we discuss the current challenges for successful RNA interference. Also, we suggested proper a strategy for delivering siRNA that can be useful in targeting therapy. Finally, the combination of a variety of anticancer drugs and siRNA through acceptable delivery systems and their effects on cell cycle and apoptosis will be evaluated.